Journal article

Publication year: 2020

Pages: 95-104

Journal: Herz: Cardiovascular Diseases

Volume number: 45

Issue number: SUPPL 1

ISSN: 0340-9937

eISSN: 1615-6692

DOI Link: https://doi.org/10.1007/s00059-019-4822-7

Publisher: Springer

Abstract: 
Background Limited data exist on bioresorbable scaffolds (BRS) in patients with acute coronary syndrome (ACS). The aim of the present study was to evaluate novolimus-eluting BRS (DESolve) as interventional treatment for patients with ACS, and to compare its 12-month outcomes with the everolimus-eluting bioresorbable scaffolds (Absorb). Methods In this retrospective study, patients with ACS (including unstable angina pectoris, ST-segment elevation myocardial infarction, or non-ST-segment elevation myocardial infarction) treated with either the Absorb or the DESolve BRS were evaluated in a 1:1 matched-pair analysis. Major adverse cardiac events (MACE), including death, myocardial infarction, and target lesion revascularization, were evaluated as a major endpoint. The occurrence of scaffold thrombosis was also assessed. Results A total of 102 patients were eligible for this analysis. The rate of MACE at 12 months was comparable between the Absorb and the DESolve group (8.3% vs. 6.8%, p = 0.738). The occurrence of target lesion revascularization (6.2% vs. 4.7%; p = 0.700) and scaffold thrombosis (4.1% vs. 2.1%; p = 0.580) was comparable as well. All instances of scaffold thrombosis occurred within 30 days of the index procedure. Conclusion In this study, similar 12-month event rates were observed for both BRS types after implantation for the treatment of ACS.

Harvard Citation style: Nef, H., Wiebe, J., Schmidt, G., Moellmann, H., Boeder, N., Doerr, O., et al. (2020) Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome, Herz: Cardiovascular Diseases, 45(SUPPL 1), pp. 95-104. https://doi.org/10.1007/s00059-019-4822-7

APA Citation style: Nef, H., Wiebe, J., Schmidt, G., Moellmann, H., Boeder, N., Doerr, O., Bauer, T., Blachutzik, F., Liebetrau, C., Elsaesser, A., Foin, N., & Hamm, C. (2020). Everolimus- vs. novolimus-eluting bioresorbable scaffolds in patients with acute coronary syndrome. Herz: Cardiovascular Diseases. 45(SUPPL 1), 95-104. https://doi.org/10.1007/s00059-019-4822-7